Trends and pattern of the utilization of cardiovascular medicines in Lithuania in 2003–2012

Background. Despite the wide use of cardiovascular (CV) drugs, CV diseases are still the leading cause of mortality and morbidity. Analysis of drug utilization gives a possibility to evaluate effectiveness of interventions. Materials and methods. The aim of the study was to evaluate CV medicines co...

Full description

Bibliographic Details
Main Authors: Ingrida Lisauskienė, Kristina Garuolienė, Jolanta Gulbinovič
Format: Article
Language:English
Published: Vilnius University Press 2014-12-01
Series:Acta Medica Lituanica
Subjects:
Online Access:https://www.journals.vu.lt/AML/article/view/21476
id doaj-5d6d8f1dcc24427a8506ae97eac3aeb3
record_format Article
spelling doaj-5d6d8f1dcc24427a8506ae97eac3aeb32021-02-03T09:25:19ZengVilnius University PressActa Medica Lituanica1392-01382029-41742014-12-0121310.6001/actamedica.v21i3.2999Trends and pattern of the utilization of cardiovascular medicines in Lithuania in 2003–2012Ingrida LisauskienėKristina GaruolienėJolanta GulbinovičBackground. Despite the wide use of cardiovascular (CV) drugs, CV diseases are still the leading cause of mortality and morbidity. Analysis of drug utilization gives a possibility to evaluate effectiveness of interventions. Materials and methods. The aim of the study was to evaluate CV medicines consumption in Lithuania in 2003–2012. Data was retrieved from the SVEIDRA database of the National Health Insurance Fund. Utilization of the following groups of CVM (ATC group C) was analyzed: C02 – antihypertensive drugs, C03 – diuretics, C07 – beta blocking agents (BBs), C08 – calcium channel blockers (CCBs), C09 – agents acting on the renin–angiotensin system, C10 – lipid modifying agents. ATC/DDD methodology was used. Data was expressed as a number of DDD per 1  000 inhabitants per day (DDD/TID). Results. Consumption of CVM went from 134.5 DDD/TID in 2003 to 352.2 in 2012. Angiotensin converting enzyme inhibitors (ACEI) were the most consumed ones (66–114.8 DDD/TID), followed by CCBs (19.4–38.8 DDD/TID) and BBs (12.5–52.6 DDD/TID).There was high consumption of antihypertensives (4.7–23.9 DDD) and low consumption of diuretics (9.4–16.9 DDD/TID) and lipid modyfing agents (0.4–7.4 DDD/TID). Increasing utilization was noticed in the angiotensin II antagonist (ARBs) group (42 DDD/TID), ACEI combinations (38.6 DDD/TID) and ARBs combinations (12.9 DDD/TID) in 2012. Conclusions. Utilization of CV medicines increased in Lithuania in 2003–2012. ACEI held the first position. An extremely low utilization of lipid modifying agents, diuretics and high consumption of alpha-receptor blockers showed the need of actions on changing the prescribing pattern of CV drugs.https://www.journals.vu.lt/AML/article/view/21476drug utilization (trends)cardiovascular medicineshypertension medicationLithuania
collection DOAJ
language English
format Article
sources DOAJ
author Ingrida Lisauskienė
Kristina Garuolienė
Jolanta Gulbinovič
spellingShingle Ingrida Lisauskienė
Kristina Garuolienė
Jolanta Gulbinovič
Trends and pattern of the utilization of cardiovascular medicines in Lithuania in 2003–2012
Acta Medica Lituanica
drug utilization (trends)
cardiovascular medicines
hypertension medication
Lithuania
author_facet Ingrida Lisauskienė
Kristina Garuolienė
Jolanta Gulbinovič
author_sort Ingrida Lisauskienė
title Trends and pattern of the utilization of cardiovascular medicines in Lithuania in 2003–2012
title_short Trends and pattern of the utilization of cardiovascular medicines in Lithuania in 2003–2012
title_full Trends and pattern of the utilization of cardiovascular medicines in Lithuania in 2003–2012
title_fullStr Trends and pattern of the utilization of cardiovascular medicines in Lithuania in 2003–2012
title_full_unstemmed Trends and pattern of the utilization of cardiovascular medicines in Lithuania in 2003–2012
title_sort trends and pattern of the utilization of cardiovascular medicines in lithuania in 2003–2012
publisher Vilnius University Press
series Acta Medica Lituanica
issn 1392-0138
2029-4174
publishDate 2014-12-01
description Background. Despite the wide use of cardiovascular (CV) drugs, CV diseases are still the leading cause of mortality and morbidity. Analysis of drug utilization gives a possibility to evaluate effectiveness of interventions. Materials and methods. The aim of the study was to evaluate CV medicines consumption in Lithuania in 2003–2012. Data was retrieved from the SVEIDRA database of the National Health Insurance Fund. Utilization of the following groups of CVM (ATC group C) was analyzed: C02 – antihypertensive drugs, C03 – diuretics, C07 – beta blocking agents (BBs), C08 – calcium channel blockers (CCBs), C09 – agents acting on the renin–angiotensin system, C10 – lipid modifying agents. ATC/DDD methodology was used. Data was expressed as a number of DDD per 1  000 inhabitants per day (DDD/TID). Results. Consumption of CVM went from 134.5 DDD/TID in 2003 to 352.2 in 2012. Angiotensin converting enzyme inhibitors (ACEI) were the most consumed ones (66–114.8 DDD/TID), followed by CCBs (19.4–38.8 DDD/TID) and BBs (12.5–52.6 DDD/TID).There was high consumption of antihypertensives (4.7–23.9 DDD) and low consumption of diuretics (9.4–16.9 DDD/TID) and lipid modyfing agents (0.4–7.4 DDD/TID). Increasing utilization was noticed in the angiotensin II antagonist (ARBs) group (42 DDD/TID), ACEI combinations (38.6 DDD/TID) and ARBs combinations (12.9 DDD/TID) in 2012. Conclusions. Utilization of CV medicines increased in Lithuania in 2003–2012. ACEI held the first position. An extremely low utilization of lipid modifying agents, diuretics and high consumption of alpha-receptor blockers showed the need of actions on changing the prescribing pattern of CV drugs.
topic drug utilization (trends)
cardiovascular medicines
hypertension medication
Lithuania
url https://www.journals.vu.lt/AML/article/view/21476
work_keys_str_mv AT ingridalisauskiene trendsandpatternoftheutilizationofcardiovascularmedicinesinlithuaniain20032012
AT kristinagaruoliene trendsandpatternoftheutilizationofcardiovascularmedicinesinlithuaniain20032012
AT jolantagulbinovic trendsandpatternoftheutilizationofcardiovascularmedicinesinlithuaniain20032012
_version_ 1724287165200859136